title: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases.
abstract: BACKGROUND
  In order to improve management, the files and tissue sections of 28 cases of malignant peripheral nerve sheath tumors (MPNST) diagnosed at the University of Virginia Health Sciences Center between 1960 and 1990 were reviewed.
  
  
  METHODS
  Clinical data tabulated included age, sex, race, the presence or absence of von Recklinghausen neurofibromatosis type 1 (NF-1), tumor size, tumor location, type of treatment, and status of surgical margins. Pathologic study included assessment of mitotic rate, divergent differentiation, cellular atypia, necrosis, and vascular reaction.
  
  
  RESULTS
  The median disease-free survival time was 11 months, and the median overall survival time was 44 months. Overall survival and disease-free survival were significantly influenced by patient age, tumor location, tumor size, extent of surgery, and quality of margins. Patients with a family history of neurofibromatosis also had better disease-free survival. None of the other clinical variables correlated with survival.
  
  
  CONCLUSIONS
  The authors recommended that patients with NF-1 be followed closely for MPNST development. For most cases, treatment should include aggressive surgery with wide surgical margins combined with adjuvant radiation therapy. Chemotherapy may have a role for treatment failures.
authors.affiliation: Department of Surgery, Bethesda Naval Hospital, Maryland.
authors.forename: J E
authors.initials: JE
authors.lastname: Wanebo
authors.forename: J M
authors.initials: JM
authors.lastname: Malik
authors.forename: S R
authors.initials: SR
authors.lastname: VandenBerg
authors.forename: H J
authors.initials: HJ
authors.lastname: Wanebo
authors.forename: N
authors.initials: N
authors.lastname: Driesen
authors.forename: J A
authors.initials: JA
authors.lastname: Persing
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008938:Mitosis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000473:pathology; D009442:Neurilemmoma / Q000473:pathology* / Q000556:secondary / Q000601:surgery; D009455:Neurofibroma / Q000473:pathology* / Q000556:secondary / Q000601:surgery; D009456:Neurofibromatosis 1 / Q000235:genetics / Q000473:pathology; D010524:Peripheral Nervous System Neoplasms / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate